Targeting BTN3A1 in vivo using CTX-2026, a unique fully human aglycosylated monoclonal antibody delayed the progression of ovarian cancer in both syngenic and xenograft models through the elicitation of more robust αβ T cell responses. The gene discussed is BTN3A1; the disease is ovarian carcinoma.